Business Standard

Monday, December 23, 2024 | 07:18 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Alembic Pharma dips 8% on disappointing June quarter results

Ebitda (earnings before interest, taxes, depreciation, and amortization) margins declined 1258 basis points (bps) YoY to 17.8 per cent, due to higher other expenditure

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing
Premium

SI Reporter Mumbai
Shares of Alembic Pharmaceuticals dipped 8 per cent to Rs 840 on the BSE in intra-day trade on Tuesday after the company reported disappointing numbers for the quarter ended June 2021 (Q1FY22), with consolidated profit after tax (PAT) declining 45.4 per cent year-on-year (YoY) to Rs 164.50 crore on weak performance of US business. The pharmaceutical company had posted a PAT of Rs 301 crore in Q1FY21.

Ebitda (earnings before interest, taxes, depreciation, and amortization) margins declined 1,258 basis points (bps) YoY to 17.8 per cent due to higher other expenditure.

The company’s revenues declined 1.1 per cent YoY to Rs 1,326

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in